In-house members
15
Total footprint
30,000sq ft
Our Old Market incubator hosts growing Deep Tech companies that have moved beyond proof of concept and are scaling their teams, typically 20–30 people strong.
This site serves as the main event venue of our Bristol campus — featuring the 1023 Bar, our community’s main stage for events and a gathering spot for informal meetups every Thursday.
Old Market members are breaking new ground in several science and engineering fields — from advanced sustainable materials to vaccine platforms and stem cell therapeutics.
With 30,000 sq ft of laboratory, office and meeting space, our Old Market incubator is a supportive, well-connected hub for growing Deep Tech companies.
This location also features a large event space, shared social spaces, and our favourite addition — the 1023 Bar, open every Thursday for the community.
Membership includes access to our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.
If you are looking for private lab and office space, get in touch to enquire about our current availability at Old Market or OMX, our newest Bristol incubator.
Travel between locations is measured in walking distance
Midland Rd & St Philips Rd
0.5 miles / 11 min
0.7 miles / 15 min
Uplift360 is developing chemical-based regeneration technologies to recover and reuse critical industrial materials such as carbon fibre and aramid. Its vision is to lead the way in circular economy innovation, creating a future where advanced materials are never wasted. Backed by the UK Defence and Security Accelerator (DASA), Luxembourg Government Directorate of Defence and Innovate UK, it enables circular and secure supply chains for high-performance sectors.
EnsiliTech is improving the shelf-life and global accessibility of vaccines and other biological therapeutics by combatting cold chain transport and storage issues. Its novel ensilication technology, designed for both existing and new biopharmaceutical formulations, encases thermally unstable biomolecules within silica nanoshells to prevent environmental degradation. This eliminates the need for cold chain requirements that are expensive, prone to failure and generate significant carbon dioxide emissions.
Argonaute RNA is developing safe, reliable and targeted methods of temporarily silencing genes in different tissue cells. It does this via the proprietary modification of small interfering RNA (siRNA), using a novel stabilisation method to overcome previous obstacles to developing siRNA drugs for healthcare.
Invivo Healthcare is developing solutions to better understand and modulate human microbiomes, promoting long-term wellness and a sustainable future of healthcare. Its supplement therapeutics are plant, nutrient and microorganism-based, designed to lead the way in combating the rise of chronic diseases and a reductionist approach to medicine.
Dimension Biotechnologies is addressing unmet global vascular health challenges by improving diagnostic tools. Its transformative technology non-invasively monitors microscopic blood vessels at the biochemical level enabling doctors, drug developers and scientists to rapidly assess microvascular health and disease.
Triple Bio is developing a new technology platform to boost milk yields and reduce methane in cattle. Its next-generation solution, RumeNRG™, uses advanced lipid technology inspired by nature to rebalance the rumen microbiome. It overcomes the limitations of current methane inhibitors by offering dual efficacy: enhanced profitability for farmers alongside a significant sustainability impact.
Glaia is developing innovative solutions to optimise agricultural plant performance to help food security and fight climate change. Using disruptive technology, its sustainable agrochemicals unlock the potential of the photosynthetic process, enabling plant cells to more efficiently convert energy to biomass to increase crop yields without increasing inputs. This results in greater profits for growers and reduced greenhouse emissions, delivering more sustainable global food production.
GenomeKey is transforming how healthcare clinicians diagnose and treat infections like sepsis to improve patient outcomes. Using cutting-edge machine learning and DNA sequencing, the company is developing a next-generation diagnostic device to identify bacterial genomes and determine their antimicrobial susceptibility directly from patient blood in just a few hours, rather than days. This enables clinicians to prescribe the right antibiotics for patients with much more efficiency and accuracy, reducing costs, minimising unnecessary antibiotic use and ultimately saving millions of lives from the world’s leading cause of death.
Kelpi is tackling plastic pollution by developing sustainable alternatives to single-use plastic packaging. It uses seaweed to create a unique bioplastic coating that provides a world-leading water barrier for new-generation packaging while being recyclable, biodegradable, and low carbon. By working with major food and drink, cosmetics and home care brands, Kelpi is already reducing reliance on fossil-fuel plastics and paving the way for a greener future in these industries.
.webp)
